A pharma client with a major oncology brand asked us to assess how a specific clinical study result for cHL disease affected the HCP perceptions of their brand versus competitors worldwide.
The challenge for the client was setting up a system for global coverage of HCPs across various sources and harvesting and analyzing them in real-time:
SetuServ’s proprietary PharmaSignals platform identified ~934 global Hematology KOLs and HCPs with an active digital presence.
57% of the HCPs are from the USA, followed by 33% of HCPs from Europe. Sources such as Twitter, Semantic Scholar, PubMed, ClinicalTrials.gov, and Oncology media sources from the US such as OncLive, TargetedOncology, and from the EU like Haematologica are covered as part of the analysis.
Analyzing the collected data of the HCPs showed that, after the interim results of the clinical study, the net sentiment of client drugs decreased significantly because of the better efficacy outcomes of the competitor’s drugs compared to the client’s drugs. In contrast, the net sentiment of competitors increased marginally.
In 2021, the net sentiment of the client’s drug improved for two reasons:
- Physicians mentioned Interim results of clinical study less frequently because it showed that competitor drugs had better efficacy outcomes
- Other clinical studies demonstrated better efficacy of the client’s drug when used in combination with other drugs, which improved the sentiment towards the client’s drug
These factors reduced the sentiment gap between the client’s drug and its competitors.
PharmaSignals will be capable of performing comparable analyses for other clinical studies or events and investigating their impact on drugs in various therapeutic areas.